Cardiovascular events in patients with deferred lesions and chronic kidney disease

被引:3
|
作者
Hata, Takehiro [1 ]
Otsuki, Hisao [1 ]
Arashi, Hiroyuki [1 ]
Nakao, Masashi [1 ]
Yamaguchi, Junichi [1 ]
机构
[1] Tokyo Womens Med Univ, Dept Cardiol, 8-1, Kawada Cho,Shinju Ku, Tokyo 1628666, Japan
关键词
Deferred lesion; Cardiovascular event; Chronic kidney disease; Coronary artery disease; FRACTIONAL FLOW RESERVE; ANGIOGRAPHY; PCI;
D O I
10.1007/s00380-023-02285-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
No study has reported the association between the worsening of chronic kidney disease (CKD) and cardiovascular events in patients with deferred coronary artery lesions. We included patients with deferred lesions, defined as a fractional flow reserve (FFR) value > 0.80 treated with conservative medical therapy. Patients were divided into three groups: group 1, CKD stages 1-2; group 2, CKD stages 3-5; and group 3, CKD stage 5D (hemodialysis), with the clinical outcomes compared. The primary endpoint was the first occurrence of target vessel myocardial infarction, ischemia-driven target-vessel revascularization, or all-cause death. The primary endpoint was noted in 17, 25, and 36 patients in groups 1, 2, and 3, respectively. Within the three groups, the incidence rate of deferred lesions was 7.0%, 10.4%, and 32.4%, respectively. No difference was observed in the incidence of the primary endpoint between groups 1 and 2 (log-rank p = 0.16). However, the patients in group 3 had a significantly higher risk for the primary endpoint than those in groups 1 and 2 (log-rank p < 0.0001). In the multivariate Cox proportional hazards model, the patients in group 3 exhibited a higher incidence of the primary endpoint than those in group 1 (HR: 2.14; 95% CI 1.02-4.49; p < 0.01). Careful management is needed in patients undergoing hemodialysis, even if coronary artery stenosis is considered a deferred lesion.
引用
收藏
页码:1364 / 1370
页数:7
相关论文
共 50 条
  • [31] Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events
    Sugiura, Sachiyo
    Inaguma, Daijo
    Kitagawa, Akimitsu
    Murata, Minako
    Kamimura, Yutaka
    Sendo, Sho
    Hamaguchi, Kyoko
    Nagaya, Hiroshi
    Tatematsu, Miho
    Kurata, Kei
    Yuzawa, Yukio
    Matsuo, Seiichi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2010, 14 (01) : 43 - 50
  • [32] MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH RECURRENT GOUT, CARDIOVASCULAR AND CHRONIC KIDNEY DISEASE, INITIATING ON ALLOPURINOL OR FEBUXOSTAT
    Foody, J.
    Turpin, R.
    Tidwell, B. A.
    Lawrence, D. F. Eisenberg
    Schulman, K. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 374 - 374
  • [33] Association of a history of acute kidney injury with major adverse cardiovascular events in chronic kidney disease patients
    Tyl, B.
    Costa, A.
    Vora, P.
    Farjat, A.
    Sandrak, P.
    Nadarajah, R.
    Wanner, C.
    Wilson, D.
    Wu, J.
    Gale, C.
    Rossignol, P.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [34] Acute kidney injury as a key predictor of major adverse cardiovascular events in chronic kidney disease patients
    Florens, Nans
    Aymes, Estelle
    Gauthier, Victoria
    Frimat, Luc
    Laville, Maurice
    Amouyel, Philippe
    Nicolas, Mansencal
    Liabeuf, Sophie
    Massy, Ziad
    Stengel, Benedicte
    De Pinho, Natalia Alencar
    Hamroun, Aghiles
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I202 - I203
  • [35] Acute kidney injury as a key predictor of major adverse cardiovascular events in chronic kidney disease patients
    Florens, Nans
    Aymes, Estelle
    Gauthier, Victoria
    Frimat, Luc
    Laville, Maurice
    Amouyel, Philippe
    Nicolas, Mansencal
    Liabeuf, Sophie
    Massy, Ziad
    Stengel, Benedicte
    de Pinho, Natalia Alencar
    Hamroun, Aghiles
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [36] Neutrophil to lymphocyte ratio independently predicts cardiovascular events in patients with chronic kidney disease
    Solak, Yalcin
    Yilmaz, Mahmut Ilker
    Sonmez, Alper
    Saglam, Mutlu
    Cakir, Erdinc
    Unal, Hilmi Umut
    Gok, Mahmut
    Caglar, Kayser
    Oguz, Yusuf
    Yenicesu, Mujdat
    Karaman, Murat
    Ay, Seyit Ahmet
    Gaipov, Abduzhappar
    Turk, Suleyman
    Vural, Abdulgaffar
    Carrero, Juan J.
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2013, 17 (04) : 532 - 540
  • [37] Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review
    Naderi, Sahar
    Foody, JoAnne M.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2012, 5 : 165 - 169
  • [38] The impact of body composition measures on survival and cardiovascular events in patients with chronic kidney disease
    Randhay, Ashveer
    Horner, Daniela Viramontes
    Fluck, Richard
    Taal, Maarten W.
    Eldehni, Tarek
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [39] Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease
    Charytan, David M.
    Solomon, Scott D.
    Ivanovich, Peter
    Remuzzi, Giuseppe
    Cooper, Mark E.
    McGill, Janet B.
    Parving, Hans-Henrik
    Parfrey, Patrick
    Singh, Ajay K.
    Burdmann, Emmanuel A.
    Levey, Andrew S.
    Eckardt, Kai-Uwe
    McMurray, John J. V.
    Weinrauch, Larry A.
    Liu, Jiankang
    Claggett, Brian
    Lewis, Eldrin F.
    Pfeffer, Marc A.
    DIABETES OBESITY & METABOLISM, 2019, 21 (05): : 1199 - 1208
  • [40] Coronary flow reserve predicts cardiovascular and cerebrovascular events in patients with chronic kidney disease
    Sakamoto, N.
    Nakazato, K.
    Kunii, H.
    Iwaya, S.
    Owada, T.
    Nakamura, Y.
    Yamauchi, H.
    Saitoh, S.
    Ishibashi, T.
    Takeishi, Y.
    EUROPEAN HEART JOURNAL, 2010, 31 : 312 - 312